tiprankstipranks
Landos Biopharma (LABP)
NASDAQ:LABP
US Market
Holding LABP?
Track your performance easily

Landos Biopharma (LABP) Income Statement

117 Followers

Landos Biopharma Income Statement

Last quarter (Q3 2023), Landos Biopharma's total revenue was $―, a decrease of ― from the same quarter last year. In Q3, Landos Biopharma's net income was $-5.86M. See Landos Biopharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 22Dec 21Dec 20Dec 19Dec 18
Total Revenue
--$ 18.00M$ 0.00$ 0.00$ 0.00
Cost of Revenue
------
Gross Profit
------
Operating Expense
$ 9.60M$ -40.56M$ -56.82M$ 30.68M$ 13.29M$ 5.93M
Operating Income
$ -22.63M$ -40.56M$ -56.82M$ -30.68M$ -13.29M$ -5.93M
Net Non Operating Interest Income Expense
$ 1.61M$ 1.26M$ 412.00K$ 455.00K$ -144.00K$ -4.00K
Other Income Expense
$ -134.00K$ -168.00K$ -17.77M$ 77.00K$ -33.00K$ -106.00K
Pretax Income
$ -21.05M$ -39.28M$ -38.42M$ -30.14M$ -13.47M$ -6.04M
Tax Provision
--$ -77.10M---
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -20.84M$ -39.11M$ -38.66M$ -30.14M$ -13.47M$ -6.04M
Basic EPS
$ -2.16$ -0.98$ -1.02$ -0.77$ -0.58$ -0.26
Diluted EPS
$ -1.79$ -0.98$ -1.02$ -0.77$ -0.58$ -0.26
Basic Average Shares
$ 117.51M$ 40.25M$ 37.56M$ 39.16M$ 23.10M$ 23.10M
Diluted Average Shares
$ 117.51M$ 40.25M$ 37.56M$ 39.16M$ 23.10M$ 23.10M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 9.60M$ -40.56M$ -56.82M$ 30.68M$ 13.29M$ 5.93M
Net Income From Continuing And Discontinued Operation
$ -20.98M$ -39.11M$ -38.66M$ -30.14M$ -13.47M$ -6.04M
Normalized Income
---$ -30.22M$ -13.43M$ -5.94M
Interest Expense
---$ 0.00$ 304.00K$ 4.00K
EBIT
$ -24.70M$ -39.28M$ -38.42M$ -30.68M$ -13.16M$ -6.04M
EBITDA
$ -24.56M$ -37.53M$ -37.05M$ -30.54M$ -13.06M$ -5.96M
Currency in USD

Landos Biopharma Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis